If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
The comments are all positive, even the nurse mentioning labels printing didn’t say anything about ‘serious risks’ they all concluded worthwhile test as gentamicin is dangerous to some people and they found positives, so saved babies hearing.
If the report is 4yrs old then it’s likely before the analysis kit was revised following early user feedback.
The design was revised following NHS feedback a while ago, not sure of exact timeline, but certainly before the NICE report last year.
There was a mention of NICE producing a timetable for full approval as the test was now being used in general hospitals and not just specialist/ICU settings, can’t remember which RNS.
The fact is nobody knows exactly what will happen next as this approval route hasn’t been used before, and let’s not forget the test avoids irreversible hearing loss and saves money, so logic suggests it’s going to be moved through whatever the process is asap!
Hi Al
That’s also what I thought, the gene that causes deafness in babies doesn’t disappear as they age, it’s just the impact of certain antibiotics is less severe, hearing loss but not totally deaf, so worth testing adults too.
Niss, we don’t need a miracle, just a bit more time, the company is a long way from what it was last year or any other year so continuing to refer back to previous price movements is pointless.
We’re first to market with world class products that should sell globally, in my opinion we should easily pass 65p once NICE approval is published and sales follow, the market cap is (relatively) peanuts!
Lloyd
You clearly have no idea what you’re invested in, it’s first to market with ground breaking and life changing new technology, potentially lifesaving. It’s (AIHL) still going through approvals process and will be worth in excess of £100m pa eventually, and save money for the health authorities adopting it, however, it’s a new process and requires up front expenditure to achieve longer term savings.
The stroke marker is potentially worth even more.
All explained in the presentation on Monday, not presented in a ‘tub-thumping’ way, but what you’d expect from a scientist and an accountant.
And you’re on here everyday with ‘turd’ and ‘dog’ comments, if you hate GDR so much why are you on here all day every day, get a job, get a life and stop the never ending negative BS
Good find, sounds like Mirnax Biosens is selling GDR kit and also, if my translation is accurate, developing their own tests for prostate cancer, Alzheimer's and Cystic Fibrosis for use in GDR kit.
Doesn't sound like a JV, but still something I'd have thought GDR would announce via RNS.
Seems good news though either way!
Lloyd88
why are you continually banging on about 'further dilution' when every communication from GDR states clearly funded into 2023? as you have also stated, there's no way the NHS won't adopt the AIHL test as they have effectively claimed it as their own success, so the need for a further raise is very remote and then wouldn't be until next year.
not a victim of anything thanks, I have a large holding that's in profit and will keep for long-term gain.
the bitter victim on here seems to be yourself, spouting negative and substantiated comments at every opportunity for whatever your agenda is.